相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study
Monica Marazuela et al.
ENDOCRINE (2022)
A Pituitary Society update to acromegaly management guidelines
Maria Fleseriu et al.
PITUITARY (2021)
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
David Cella et al.
ADVANCES IN THERAPY (2021)
More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
Maria Fleseriu et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients)
Sara Barraud et al.
ANNALES D ENDOCRINOLOGIE (2021)
Patient-Centered Outcomes with Pituitary and Parasellar Disease
Susan M. Webb et al.
NEUROENDOCRINOLOGY (2020)
Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey
Pedro de Pablos-Velasco et al.
PITUITARY (2020)
Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison
Chiara Whichello et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2020)
Acromegaly and the information gap: patient perceptions of the journey from primary to tertiary care
Hei Yi Vivian Pak et al.
ENDOCRINE CONNECTIONS (2020)
Acromegaly
Annamaria Colao et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review
Vikas Soekhai et al.
DRUG DISCOVERY TODAY (2019)
AcroVoice: eliciting the patients' perspective on acromegaly disease activity
Yanina Jackson et al.
PITUITARY (2019)
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment
Francesco Ferrau et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus
Ignacio Bernabeu et al.
ENDOCRINOLOGIA DIABETES Y NUTRICION (2018)
Update on quality of life in patients with acromegaly
Iris Crespo et al.
PITUITARY (2017)
Quality of life tools for the management of pituitary disease
Susan M. Webb et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly
Aart J. van der Lely et al.
PITUITARY (2017)
Patients' preferences for primary health care - a systematic literature review of discrete choice experiments
Kim-Sarah Kleij et al.
BMC HEALTH SERVICES RESEARCH (2017)
Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study
Nikolaos Kyriakakis et al.
CLINICAL ENDOCRINOLOGY (2017)
Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
Maria Fleseriu et al.
ENDOCRINE (2017)
Quality of Life in Acromegaly
Susan M. Webb et al.
NEUROENDOCRINOLOGY (2016)
Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly
Julie M. Silverstein
PITUITARY (2016)
Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
Cecilia Follin et al.
ENDOCRINE CONNECTIONS (2016)
Treatment of acromegaly in the era of personalized and predictive medicine
Manuel Puig Domingo
CLINICAL ENDOCRINOLOGY (2015)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Impact of treatment satisfaction on quality of life of patients with acromegaly
Hasan Kepicoglu et al.
PITUITARY (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Andrea Giustina et al.
PLOS ONE (2012)
Affected Illness Perceptions and the Association with Impaired Quality of Life in Patients with Long-Term Remission of Acromegaly
Jitske Tiemensma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant
S. J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Extensive clinical experience: Changing patterns in diagnosis and therapy of acromegaly over two decades
Lisa Nachtigall et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Interventions for enhancing medication adherence
R. B. Haynes et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2008)
Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL)
R Trepp et al.
CLINICAL ENDOCRINOLOGY (2005)
Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly:: development and psychometric properties
SM Webb et al.
CLINICAL ENDOCRINOLOGY (2002)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
